News & Updates
Filter by Specialty:
L-MOCA: Olaparib maintenance for ovarian cancer benefits Asians
Maintenance monotherapy with olaparib appears safe and effective in Asian patients with platinum-sensitive relapsed (PSR) ovarian cancer, regardless of their BRCA status, as shown in the results of the phase III, open-label, single-arm L-MOCA study.
L-MOCA: Olaparib maintenance for ovarian cancer benefits Asians
07 Jul 2022
Post-transplant KRd a new SoC for MM?
In the ongoing phase III ATLAS study evaluating patients with newly diagnosed multiple myeloma (MM), progression-free survival (PFS) was better with maintenance treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) than lenalidomide (R) alone after autologous stem-cell transplantation (ASCT).
Post-transplant KRd a new SoC for MM?
07 Jul 2022
Diabetes status may influence long-term survival in metastatic breast cancer
Long-term overall survival (OS) in patients with metastatic breast cancer (MBC) may be influenced by diabetes status, according to a retrospective study presented at ENDO 2022.
Diabetes status may influence long-term survival in metastatic breast cancer
06 Jul 2022
Bariatric surgery cuts obesity-associated cancer, cancer death risks
For individuals with obesity, undergoing weight-loss surgery may be a lifesaver, not only helping avert cancer-related deaths but also preventing the incidence of obesity-associated cancer, according to data from the SPLENDID (Surgical Procedures and Long-term Effectiveness in Neoplastic Disease Incidence and Death) study.
Bariatric surgery cuts obesity-associated cancer, cancer death risks
06 Jul 2022
Surgery helps avoid castrate-resistant state in men with metastatic prostate cancer
In men with metastatic prostate cancer, prior radical prostatectomy (RP) appears to reduce the risk of developing a castrate-resistant state, as compared with radiation therapy (RT), according to a recent study. Previous RP also seems to improve overall survival (OS).
Surgery helps avoid castrate-resistant state in men with metastatic prostate cancer
05 Jul 2022
Stage II CRC: ctDNA guidance reduces adjuvant chemo use, does not increase recurrence
Using circulating tumour DNA (ctDNA) analysis to guide adjuvant treatment of stage II colorectal cancer (CRC) reduces adjuvant chemotherapy use without compromising recurrence-free survival (RFS) compared with standard management guided by clinicopathological criteria, results of a phase II randomized controlled trial have shown.
Stage II CRC: ctDNA guidance reduces adjuvant chemo use, does not increase recurrence
05 Jul 2022
Concurrent DOAC, tamoxifen use poses no elevated bleeding risk
In breast cancer patients receiving direct oral anticoagulants (DOACs), tamoxifen is safe to use and does not increase the risk of haemorrhage as compared with concurrent use of an aromatase inhibitor (AI), a study has found.
